Fredun Pharmaceuticals Limited

BSE:539730 Stock Report

Market Cap: ₹3.3b

Fredun Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Fredun Pharmaceuticals has been growing earnings at an average annual rate of 46.1%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 28.5% per year. Fredun Pharmaceuticals's return on equity is 13.5%, and it has net margins of 4.5%.

Key information

46.1%

Earnings growth rate

42.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate28.5%
Return on equity13.5%
Net Margin4.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Fredun Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:539730 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,9031773550
30 Jun 243,6491743560
31 Mar 243,4821563450
31 Dec 234,4251834530
30 Sep 233,0041302820
30 Jun 232,8741231180
31 Mar 232,7471082780
31 Dec 221,49858210-1
30 Sep 222,423832600
30 Jun 222,250701091
31 Mar 222,245632560
31 Dec 211,957391871
30 Sep 211,877331820
30 Jun 211,655231820
31 Mar 211,338201770
31 Dec 201,15520190-1
30 Sep 20966171870
30 Jun 20963171820
31 Mar 201,127191740
31 Dec 191,177322181
30 Sep 191,177392150
30 Jun 191,074532200
31 Mar 19961452270
31 Dec 1884541900
30 Sep 1872026820
30 Jun 186528810
31 Mar 18584181200
31 Dec 1755214610
30 Sep 1754113670
30 Jun 1749312490
31 Mar 1756714620
31 Dec 1655215570
30 Sep 1655216510
30 Jun 1650913390
31 Mar 1642311480
31 Dec 153384400
30 Sep 152694380
30 Jun 152784380
31 Mar 152533370
31 Dec 142406350
30 Sep 142384350
30 Jun 142284340
31 Mar 142132320
31 Dec 131781270

Quality Earnings: 539730 has a high level of non-cash earnings.

Growing Profit Margin: 539730's current net profit margins (4.5%) are higher than last year (4.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 539730's earnings have grown significantly by 46.1% per year over the past 5 years.

Accelerating Growth: 539730's earnings growth over the past year (35.6%) is below its 5-year average (46.1% per year).

Earnings vs Industry: 539730 earnings growth over the past year (35.6%) exceeded the Pharmaceuticals industry 20%.


Return on Equity

High ROE: 539730's Return on Equity (13.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies